Patient reported outcomes in Triple Class Exposed, Relapsed/Refractory Multiple Myeloma (TCE RRMM) patients in KarMMa 3 trial (Phase 3 RCT): idecabtagene Vicleucel (ide-cel) versus standard regimens

被引：0

作者：

Einsele, H. ^{[1
]}

Delforge, M. ^{[2
]}

Patel, K. ^{[3
]}

Eliason, L. ^{[4
]}

Dhanda, D. ^{[4
]}

Shi, L. ^{[5
]}

Guo, S. ^{[5
]}

Marshall, T. ^{[4
]}

Arnulf, B. ^{[6
]}

Cavo, M. ^{[7
]}

Nooka, A. ^{[8
]}

Manier, S. ^{[9
]}

Callander, N. ^{[10
]}

Giralt, S. ^{[11
]}

Ailawadhi, S. ^{[12
]}

McKiver, Popa M. ^{[4
]}

Cook, M. ^{[13
]}

Rodriguez Otero, P. ^{[14
]}

机构：

[1] Uniklinikum Wurzburg, Med Klin & Poliklin 2, Wurzburg, Germany

[2] Univ Hosp Leuven, Leuven, Belgium

[3] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA

[4] Bristol Myers Squibb, Princeton, NJ USA

[5] Evidera, Bethesda, MD USA

[6] Hop St Louis, Paris, France

[7] Bologna Univ, Sch Med, Seragnoli Inst Hematol, Bologna, Italy

[8] Emory Univ, Winship Canc Inst, Atlanda, GA USA

[9] Ctr Hosp Univ Lille, Lille, France

[10] Univ Wisconsin Hlth, Madison, WI USA

[11] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA

[12] Mayo Clin, Jacksonville, FL 32224 USA

[13] Celgene Int Sarl, Boudry, Switzerland

[14] Clin Univ Navarra, Pamplona, Spain

来源：

ONCOLOGY RESEARCH AND TREATMENT | 2023年 / 46卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

V545

引用

页码：83 / 83

页数：1

共 50 条

[41] Phase 2 results of idecabtagene vicleucel (ide-cel, bb2121) in Japanese patients with relapsed and refractory multiple myeloma
Minakata, Daisuke
Ishida, Tadao
Ando, Kiyoshi
Suzuki, Rikio
Tanaka, Junji
Hagiwara, Shotaro
Ananthakrishnan, Revathi
Kuwayama, Shigeki
Nishio, Mitsufumi
Kanda, Yoshinobu
Suzuki, Kenshi
INTERNATIONAL JOURNAL OF HEMATOLOGY, 2023, 117 (05) : 729 - 737
[42] Phase 2 results of idecabtagene vicleucel (ide-cel, bb2121) in Japanese patients with relapsed and refractory multiple myeloma
Daisuke Minakata
Tadao Ishida
Kiyoshi Ando
Rikio Suzuki
Junji Tanaka
Shotaro Hagiwara
Revathi Ananthakrishnan
Shigeki Kuwayama
Mitsufumi Nishio
Yoshinobu Kanda
Kenshi Suzuki
International Journal of Hematology, 2023, 117 : 729 - 737
[43] Estimation of post-infusion costs of care for patients in the US with relapsed and refractory multiple myeloma (RRMM) who received idecabtagene vicleucel (ide-cel, bb2121) in the KarMMa clinical trial
McGarvey, November
Ung, Brian
Carattini, Thomas
Campbell, Timothy
Lee, Abraham
Patwardhan, Pallavi
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S181 - S181
[44] Validation of prototype biomarkers to identify risk factors of inflammatory adverse events (iAEs) following idecabtagene vicleucel (ide-cel) infusion in patients with relapsed and refractory multiple myeloma (RRMM) in KarMMa-3.
Sengupta, Sanhita
Amorosi, Clara
Takhar, Mandeep
Lin, Yi
Manier, Salomon
Baz, Rachid C.
Juluri, Krishna Rangadhamarao
Kaeding, Allison
Mashadi-Hossein, Afshin
Piasecki, Julia
Campbell, Timothy Brandon
Kaiser, Shari
Rytlewski, Julie
Shamsuzzaman, Md
Martin, Nathan
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[45] Idecabtagene Vicleucel (ide-cel, bb2121), A BCMA-Directed Car T cell therapy, in patients with Relapsed and Refractory Multiple Myeloma (RRMM): Initial KarMMa results
Einsele, H.
Weisel, K.
Goldschmidt, H.
Munshi, N. C.
Anderson, L. D., Jr.
Shah, N.
Jagannath, S.
Berdeja, J.
Lonial, S.
Raje, N.
Siegel, D. S.
Lin, Y.
Oriol, A.
Moreau, P.
Yakoub-Agha, I
Delforge, M.
Petrocca, F.
Connarn, J. N.
Patel, P.
Huang, L.
Campbell, T. B.
Hege, K.
San Miguel, J.
ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 (SUPPL 4) : 90 - 91
[46] Idecabtagene Vicleucel (ide-cel, bb2121) in Relapsed and Refractory Multiple Myeloma: Analyses of High-Risk Subgroups in the KarMMa Study
Raje, Noopur S.
Siegel, David S.
Jagannath, Sundar
Lonial, Sagar
Munshi, Nikhil C.
Moreau, Philippe
Goldschmidt, Hartmut
Cavo, Michele
Truppel-Hartmann, Anna
Rowe, Everton
Huang, Liping
Agarwal, Amit
Wang, Julie
Campbell, Timothy B.
San-Miguel, Jesus F.
Reece, Donna E.
BLOOD, 2020, 136
[47] Plain Language Summary of the KarMMa-3 study of ide-cel or standard of care regimens in people with relapsed or refractory multiple myeloma
Rodriguez-Otero, Paula
Ailawadhi, Sikander
Arnulf, Bertrand
Patel, Krina
Cavo, Michele
Nooka, Ajay K.
Manier, Salomon
Callander, Natalie
Costa, Luciano J.
Vij, Ravi
Bahlis, Nizar J.
Moreau, Philippe
Solomon, Scott R.
Delforge, Michel
Berdeja, Jesus
Truppel-Hartmann, Anna
Yang, Zhihong
Favre-Kontula, Linda
Wu, Fan
Piasecki, Julia
Cook, Mark
Giralt, Sergio
FUTURE ONCOLOGY, 2024, 20 (18) : 1221 - 1235
[48] Real-life experiences with CAR T-cell therapy with idecabtagene vicleucel (ide-cel) for triple-class exposed relapsed/refractory multiple myeloma patients
Sanoyan, Dilara Akhoundova
Seipel, Katja
Bacher, Ulrike
Kronig, Marie-Noelle
Porret, Naomi
Wiedemann, Gertrud
Daskalakis, Michael
Pabst, Thomas
BMC CANCER, 2023, 23 (01)
[49] Real-life experiences with CAR T-cell therapy with idecabtagene vicleucel (ide-cel) for triple-class exposed relapsed/refractory multiple myeloma patients
Dilara Akhoundova Sanoyan
Katja Seipel
Ulrike Bacher
Marie-Noelle Kronig
Naomi Porret
Gertrud Wiedemann
Michael Daskalakis
Thomas Pabst
BMC Cancer, 23
[50] Health-related quality of life in patients with triple-class exposed relapsed and refractory multiple myeloma treated with idecabtagene vicleucel or standard regimens: patient-reported outcomes from the phase 3, randomised, open-label KarMMa-3 clinical trial
Delforge, Michel
Patel, Krina
Eliason, Laurie
Dhanda, Devender
Shi, Ling
Guo, Shien
Marshall, Thomas S.
Arnulf, Bertrand
Cavo, Michele
Nooka, Ajay
Manier, Salomon
Callander, Natalie
Giralt, Sergio
Einsele, Hermann
Ailawadhi, Sikander
Mckiver, Mihaela Popa
Cook, Mark
Rodriguez-Otero, Paula
LANCET HAEMATOLOGY, 2024, 11 (03): : e216 - e227

← 1 2 3 4 5 →